Thailand supplement ingredient approval determines whether a formula is permissible before any other review begins. A supplement formula that is compliant in its home market can be unsellable in Thailand before a single claim is reviewed. Thailand sets maximum levels for vitamins and minerals on a positive list, and an ingredient with little history of food use triggers a separate safety assessment. The ingredient question is settled first, because no amount of dossier quality rescues a formula that is not permitted.
Thailand maintains a positive list with maximum permitted levels for vitamins and minerals in food supplements. The current levels are set in the annex to MOPH Notification No. 448 B.E. 2566 (2023), which amended the food supplement rules and took effect on 2 July 2024. A formula must sit within these ceilings, and for products whose purpose is to deliver a nutrient, above a minimum floor.
No. 448 increased several ceilings. Vitamin C moved from 60 mg to 1,000 mg, Vitamin D from 5 to 15 micrograms, Vitamin B1 from 1.5 mg to 100 mg, Vitamin B12 from 2 to 600 micrograms, and Biotin from 150 to 900 micrograms.
For a supplement whose purpose is to provide a vitamin or mineral, the amount must be not less than 15 percent of the Thai reference daily intake, while staying within the annex ceiling.
Products on the market under the previous levels have a transition window to 1 July 2027, after which the current ceilings apply without exception.
A dose that is standard in another market can sit above a Thai ceiling. The fix is reformulation, which is a structural change, not a labeling edit.
An ingredient that has been used as human food for under 15 years is treated as novel food in Thailand, under MOPH No. 376 B.E. 2559 (2016). A novel ingredient cannot simply be included in a supplement. It requires a safety assessment by an FDA-recognized risk-assessment center before the product can proceed. For a manufacturer working with a newer botanical, extract, or compound, this is the difference between a routine registration and a long, evidence-heavy process, and it needs to be identified at the outset, not discovered mid-review.
Thailand's approach follows the ASEAN framework for traditional medicines and health supplements, including the principles for establishing maximum levels of vitamins and minerals. For a manufacturer selling across Southeast Asia, this means the Thai ceilings are not arbitrary, and work done to meet them often informs requirements in neighboring markets. It also means the ceilings move as the regional framework evolves, which is why a formula assessment should be current, not based on a prior year's limits.
We assess a formula against Thailand's positive list and maximum levels before anything is submitted, and we tell the client plainly whether each ingredient is permitted, capped, or novel.
When an ingredient sits above a Thai ceiling or triggers novel food assessment, we say so at the start, while reformulation or an evidence plan is still a manageable decision rather than a mid-review crisis.
For manufacturers selling across the region, we frame the Thai requirements in the context of the ASEAN framework, so the work done for Thailand is not isolated from the wider market plan.